<p>根據 Securities and Exchange Commission 最近的 13F 表格，Saratoga Research &amp; Investment Management 在第二季度將其在羅氏控股公司（OTCMKTS:RHHBY - 免費報告）的持股減少了 2.2%。該公司在此期間出售了 44,075 股後，持有 1,978,134 股羅氏股票。羅氏佔 Saratoga Research &amp; Investment Management 投資組合的 4.3%，是其第九大持股。截至其最近的 SEC 備案，Saratoga Research &amp; Investment Management 在羅氏的持股價值為 80,629,000 美元。</p>
<ul>
<li>3 只在美國投資超過 1000 億美元的大型製藥股。</li>
</ul>
<p>其他一些對沖基金最近也調整了對該公司的持股。Rhumbline Advisers 在第一季度將其在羅氏的持股增加了 7.4%。Rhumbline Advisers 現在持有 107,252 股羅氏股票，價值 4,413,000 美元，此前在此期間又購買了 7,374 股。OLD National Bancorp IN 在第二季度將其在羅氏的股份增加了 2.9%。OLD National Bancorp IN 現在持有 261,317 股羅氏股票，價值 10,604,000 美元，此前在此期間又購買了 7,326 股。Enterprise Financial Services Corp 在第二季度購買了羅氏的新頭寸，價值約 208,000 美元。FineMark National Bank &amp; Trust 在第二季度購買了羅氏的新頭寸，價值約 210,000 美元。最後，North Star Asset Management Inc.在第二季度將其在羅氏的股份增加了 52.0%。North Star Asset Management Inc.現在持有 26,305 股羅氏股票，價值 1,072,000 美元，此前在此期間又收購了 9,000 股。</p>
<h2>分析師設定新目標價</h2>
<p>一些研究公司對 RHHBY 發表了評論。摩根大通在 12 月 8 日的研究報告中將羅氏的股票評級從 “減持” 上調至 “中性”。摩根士丹利在 12 月 2 日的報告中重申了對羅氏股票的 “減持” 評級。Zacks Research 在 12 月 5 日的研究報告中將羅氏的評級從 “持有” 下調至 “強烈賣出”。滙豐銀行在週三重申了 “買入” 評級，並對羅氏股票設定了 57.00 美元的目標價。最後，德意志銀行在 11 月 11 日的研究報告中將羅氏的評級從 “賣出” 上調至 “持有”。三位分析師給予該股票 “強烈買入” 評級，一位給予 “買入” 評級，兩位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat，該股票的平均評級為 “適度買入”，平均目標價為 57.00 美元。</p>
<ul>
<li>Viking Therapeutics：GLP-1 製造商會在批准前被收購嗎？</li>
</ul>
<p><strong>獲取我們關於 RHHBY 的最新股票報告</strong></p>
<h2>羅氏股票表現</h2>
<p>羅氏股票在週五開盤價為 50.04 美元。羅氏控股公司在過去 12 個月的最低價為 34.10 美元，最高價為 50.67 美元。該公司的 50 日移動平均價格為 45.44 美元，200 日移動平均價格為 42.31 美元。</p>
<h2>羅氏簡介</h2>
<p>（免費報告）</p>
<ul>
<li>NVIDIA 投資了這兩隻 AI 股票，你應該投資嗎？</li>
</ul>
<p>羅氏控股公司在歐洲、北美、拉丁美洲、亞洲、非洲、澳大利亞和大洋洲從事製藥和診斷業務。該公司在貧血、血液和實體腫瘤、皮膚病、血友病、炎症和自身免疫、神經系統疾病、眼科、呼吸系統疾病和移植等治療領域提供藥品。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票超過羅氏</li>
<li>什麼是支撐位？</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
<li>大型股的定義及如何投資</li>
<li>為什麼亞馬遜可能在幾周內成為 300 美元的股票</li>
<li>為什麼股票行業對成功投資至關重要？</li>
<li>Adobe 在財報後獲得提振：長期前景看漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在羅氏嗎？</h2>
<p>在考慮羅氏之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而羅氏並不在名單上。</p>
<p>雖然羅氏目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得投資。</p>
<p>在這裏查看這五隻股票</p>

羅氏(ADR)

Saratoga投資

<p>Saratoga 投資管理在第二季度減少了對羅氏 (ADR) 的持股 2.2%，目前持有 1,978,134 股，價值 8063 萬美元。羅氏是該公司的第九大持股，佔其投資組合的 4.3%。其他對沖基金也調整了在羅氏的頭寸。分析師對羅氏的評級褒貶不一，平均評級為 “適度買入”，目標價格為 57.00 美元</p>

<p>Saratoga Research &amp; Investment Management cut its holdings in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 2.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,978,134 shares of the company's stock after selling 44,075 shares during the period. Roche accounts for 4.3% of Saratoga Research &amp; Investment Management's portfolio, making the stock its 9th largest holding. Saratoga Research &amp; Investment Management's holdings in Roche were worth $80,629,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根據 Securities and Exchange Commission 最近的 13F 表格，Saratoga Research &amp; Investment Management 在第二季度將其在羅氏控股公司（OTCMKTS:RHHBY - 免費報告）的持股減少了 2.2%。該公司在此期間出售了 44,075 股後，持有 1,978,134 股羅氏股票。羅氏佔 Saratoga Research &amp; Investment Management 投資組合的 4.3%，是其第九大持股。截至其最近的 SEC 備案，Saratoga Research &amp; Investment Management 在羅氏的持股價值為 80,629,000 美元。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只在美國投資超過 1000 億美元的大型製藥股。</li>
</ul>
</div><p>A number of other hedge funds have also recently modified their holdings of the business. Rhumbline Advisers raised its holdings in Roche by 7.4% in the 1st quarter. Rhumbline Advisers now owns 107,252 shares of the company's stock worth $4,413,000 after purchasing an additional 7,374 shares during the period. OLD National Bancorp IN raised its stake in shares of Roche by 2.9% in the second quarter. OLD National Bancorp IN now owns 261,317 shares of the company's stock worth $10,604,000 after buying an additional 7,326 shares during the period. Enterprise Financial Services Corp bought a new position in shares of Roche in the second quarter worth about $208,000. FineMark National Bank &amp; Trust purchased a new position in shares of Roche during the 2nd quarter valued at about $210,000. Finally, North Star Asset Management Inc. grew its stake in shares of Roche by 52.0% during the 2nd quarter. North Star Asset Management Inc. now owns 26,305 shares of the company's stock valued at $1,072,000 after acquiring an additional 9,000 shares during the period.</p>
<div class="lb-trans"><p>其他一些對沖基金最近也調整了對該公司的持股。Rhumbline Advisers 在第一季度將其在羅氏的持股增加了 7.4%。Rhumbline Advisers 現在持有 107,252 股羅氏股票，價值 4,413,000 美元，此前在此期間又購買了 7,374 股。OLD National Bancorp IN 在第二季度將其在羅氏的股份增加了 2.9%。OLD National Bancorp IN 現在持有 261,317 股羅氏股票，價值 10,604,000 美元，此前在此期間又購買了 7,326 股。Enterprise Financial Services Corp 在第二季度購買了羅氏的新頭寸，價值約 208,000 美元。FineMark National Bank &amp; Trust 在第二季度購買了羅氏的新頭寸，價值約 210,000 美元。最後，North Star Asset Management Inc.在第二季度將其在羅氏的股份增加了 52.0%。North Star Asset Management Inc.現在持有 26,305 股羅氏股票，價值 1,072,000 美元，此前在此期間又收購了 9,000 股。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of research firms have commented on RHHBY. JPMorgan Chase &amp; Co. upgraded shares of Roche from an &#34;underweight&#34; rating to a &#34;neutral&#34; rating in a research note on Monday, December 8th. Morgan Stanley reaffirmed an &#34;underweight&#34; rating on shares of Roche in a report on Tuesday, December 2nd. Zacks Research lowered Roche from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Friday, December 5th. HSBC restated a &#34;buy&#34; rating and issued a $57.00 price objective on shares of Roche in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft raised Roche from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, November 11th. Three analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $57.00.</p>
<div class="lb-trans"><p>一些研究公司對 RHHBY 發表了評論。摩根大通在 12 月 8 日的研究報告中將羅氏的股票評級從 “減持” 上調至 “中性”。摩根士丹利在 12 月 2 日的報告中重申了對羅氏股票的 “減持” 評級。Zacks Research 在 12 月 5 日的研究報告中將羅氏的評級從 “持有” 下調至 “強烈賣出”。滙豐銀行在週三重申了 “買入” 評級，並對羅氏股票設定了 57.00 美元的目標價。最後，德意志銀行在 11 月 11 日的研究報告中將羅氏的評級從 “賣出” 上調至 “持有”。三位分析師給予該股票 “強烈買入” 評級，一位給予 “買入” 評級，兩位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat，該股票的平均評級為 “適度買入”，平均目標價為 57.00 美元。</p>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：GLP-1 製造商會在批准前被收購嗎？</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on RHHBY</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 RHHBY 的最新股票報告</strong></p>
</div><h2>Roche Stock Performance</h2>
<div class="lb-trans"><h2>羅氏股票表現</h2>
</div><p>Shares of Roche stock opened at $50.04 on Friday. Roche Holding AG has a twelve month low of $34.10 and a twelve month high of $50.67. The business has a 50-day moving average price of $45.44 and a 200-day moving average price of $42.31.</p>
<div class="lb-trans"><p>羅氏股票在週五開盤價為 50.04 美元。羅氏控股公司在過去 12 個月的最低價為 34.10 美元，最高價為 50.67 美元。該公司的 50 日移動平均價格為 45.44 美元，200 日移動平均價格為 42.31 美元。</p>
</div><h2>Roche Profile</h2>
<div class="lb-trans"><h2>羅氏簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><ul>
<li>NVIDIA Invested in These 2 AI Stocks, Should You?</li>
</ul>
<div class="lb-trans"><ul>
<li>NVIDIA 投資了這兩隻 AI 股票，你應該投資嗎？</li>
</ul>
</div><p>Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.</p>
<div class="lb-trans"><p>羅氏控股公司在歐洲、北美、拉丁美洲、亞洲、非洲、澳大利亞和大洋洲從事製藥和診斷業務。該公司在貧血、血液和實體腫瘤、皮膚病、血友病、炎症和自身免疫、神經系統疾病、眼科、呼吸系統疾病和移植等治療領域提供藥品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Roche</li>
<li>What is a support level?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過羅氏</li>
<li>什麼是支撐位？</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
<li>大型股的定義及如何投資</li>
<li>為什麼亞馬遜可能在幾周內成為 300 美元的股票</li>
<li>為什麼股票行業對成功投資至關重要？</li>
<li>Adobe 在財報後獲得提振：長期前景看漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=OTCMKTS&amp;Symbol=RHHBY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Roche Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在羅氏嗎？</h2>
</div><p>Before you consider Roche, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮羅氏之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而羅氏並不在名單上。</p>
</div><p>While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然羅氏目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得投資。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Saratoga Research & Investment Management 在羅氏控股股份公司持有價值 8063 萬美元的頭寸